Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform the treatment of autoimmune diseases, including type 1 diabetes, and cancer by developing allogeneic, iPSC-derived cell therapies.
PRESS RELEASES + EVENTS
view all
November 12, 2026
Century Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 62…
October 14, 2026
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
PHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) — Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology…
About us
We are building an industry-leading, allogeneic, iPSC-derived cell therapy platform for autoimmune diseases, including type 1 diabetes, and cancer.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
